Liquidia Technologies grows sequentially by 44% - YUTREPIA rapidly increases market share!
Reading Time: 3 minutes
The main product YUTREPIA grows sequentially by 44% and increased its share in a $2 billion market for inhaled prostacyclines to 23% within one year. The pipeline with the Phase III study for L606 and the expansion into new indications is expected to support a revenue target of $1 billion by 2027. Even after the breakout to an all-time high, analysts see further price potential of around 30%. Liquidia Technologies (LQDA) focuses on the development and marketing of innovative inhalation therapies for the treatment of severe lung...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
